Dianthus Therapeutics DNTH Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $51.09M+124% | $22.79M-82.8% | $132.33M+761% | $15.37M-88.3% | ||
| $353.21M+39.9% | $252.45M+510% | $41.39M-31.2% | $60.13M+32.8% | ||
| $52K— | $0-100% | $294K-93.7% | $4.7M— | ||
| $409.44M+45.8% | $280.9M+58.3% | $177.45M+116% | $82.03M-54.6% | ||
| $296K+52.6% | $194K+4.9% | $185K+30.3% | $142K-98.1% | ||
| $530.92M+42.0% | $374.01M+108% | $179.41M+116% | $83.11M-56.2% | ||
| $5.77M+202% | $1.91M— | $0-100% | $791K— | ||
| $30.73M+66.6% | $18.45M+91.6% | $9.63M+17.1% | $8.23M-24.3% | ||
| $37.52M+74.3% | $21.53M+104% | $10.54M+11.4% | $9.45M-45.2% | ||
| $43K+38.7% | $31K+107% | $15K— | $0-100% | ||
| -$336.73M-93.1% | -$174.39M-95.0% | -$89.42M-95.0% | -$45.87M+85.9% | ||
| $493.4M+40.0% | $352.48M+109% | $168.87M+481% | -$44.37M-157% | ||
| $530.92M+42.0% | $374.01M+108% | $179.41M+116% | $83.11M-56.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Dianthus Therapeutics cover its short-term obligations?
- Its current ratio is 29.25 — current assets exceed current liabilities.
- Where does Dianthus Therapeutics's balance sheet data come from?
- Every line is extracted from Dianthus Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.